Mymetics Corp
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.003
- Today's High:
- $0.003
- Open Price:
- $0.003
- 52W Low:
- $0.0009
- 52W High:
- $0.0464
- Prev. Close:
- $0.003
- Volume:
- 36000
Company Statistics
- Market Cap.:
- $820146
- Book Value:
- -0.245
- Revenue TTM:
- $705000
- Operating Margin TTM:
- -241.84%
- Gross Profit TTM:
- $1.03 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -27.04%
- Return on Equity TTM:
- 0%
Company Profile
Mymetics Corp had its IPO on 1995-03-30 under the ticker symbol MYMX.
The company operates in the Healthcare sector and Biotechnology industry. Mymetics Corp has a staff strength of 2 employees.
Stock update
Shares of Mymetics Corp opened at $0 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0 - $0, and closed at $0.
This is a 0% increase from the previous day's closing price.
A total volume of 36,000 shares were traded at the close of the day’s session.
In the last one week, shares of Mymetics Corp have increased by +114.29%.
Mymetics Corp's Key Ratios
Mymetics Corp has a market cap of $820146, indicating a price to book ratio of 0 and a price to sales ratio of 12.1723.
In the last 12-months Mymetics Corp’s revenue was $705000 with a gross profit of $1.03 million and an EBITDA of $-1692000. The EBITDA ratio measures Mymetics Corp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Mymetics Corp’s operating margin was -241.84% while its return on assets stood at -27.04% with a return of equity of 0%.
In Q2, Mymetics Corp’s quarterly earnings growth was a positive 0% while revenue growth was a negative 37.7%.
Mymetics Corp’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.07 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Mymetics Corp’s profitability.
Mymetics Corp stock is trading at a EV to sales ratio of 27720.1203 and a EV to EBITDA ratio of -35.0296. Its price to sales ratio in the trailing 12-months stood at 12.1723.
Mymetics Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $533000.00
- Total Liabilities
- $74.84 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Mymetics Corp ended 2024 with $533000.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $533000.00 while shareholder equity stood at $-74451000.00.
Mymetics Corp ended 2024 with $0 in deferred long-term liabilities, $74.84 million in other current liabilities, in common stock, $-112101000.00 in retained earnings and $0.00 in goodwill. Its cash balance stood at $402000.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $144000.00.
Mymetics Corp’s total current assets stands at $493000.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $42000.00 compared to accounts payable of $659000.00 and inventory worth $0.
In 2024, Mymetics Corp's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Mymetics Corp paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0
- 52-Week High
- $0.0464
- 52-Week Low
- $0.0009
- Analyst Target Price
- $
Mymetics Corp stock is currently trading at $0 per share. It touched a 52-week high of $0.0464 and a 52-week low of $0.0464. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.01 and 200-day moving average was $0.02 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 5342.2% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Mymetics Corp
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company’s product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, malaria, and chikungunya. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.